Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07787689
NA

Intermittent vs Alternate Daily Regimen of Prednisolone in Ambulatory Boys With Duchenne Muscular Dystrophy

Sponsor: Muhammad Aamir Latif

View on ClinicalTrials.gov

Summary

The alternate-day regimen is hypothesized to reduce hypothalamic-pituitary-adrenal (HPA) axis suppression and decrease steroid-related toxicity. Similarly, intermittent regimens aim to provide periodic steroid exposure sufficient for muscle preservation while allowing recovery periods to limit side effects. There is a critical need for localized, prospective data to determine which protocol offers the optimal balance of efficacy and safety for pediatric patients in Pakistan.

Official title: Efficacy and Safety of Intermittent vs. Alternate Daily Regimen of Prednisolone in Ambulatory Boys With Duchenne Muscular Dystrophy: A Randomized, Open-Label Trial

Key Details

Gender

MALE

Age Range

4 Years - 10 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2026-09-15

Completion Date

2027-03-15

Last Updated

2026-08-26

Healthy Volunteers

No

Interventions

DRUG

Alternate-day prednisolone

Patients will be given alternate-day administration of prednisolone at a dose of 0.75 mg/kg/day.

DRUG

Intermittent prednisolone

Patients will be administered prednisolone at a dose of 0.75 mg/kg/day for 10 consecutive days, followed by a 10-day steroid-free period.

Locations (1)

Children's Hospital/University of Child Health Sciences

Lahore, Punjab Province, Pakistan